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Objective. To audit a single center consecutive series of infrapopliteal composite bypasses with second generation glutar-
aldehyde stabilized human umbilical vein.
Design. Retrospective study.
Patients. From January 1996 to July 2006 89 femoro-distal bypasses were constructed in 85 patients with HUV and
residual vein segments as composite grafts in the absence of sufficient length of autologous vein.
Methods. All patients with infrainguinal bypass operations were registered prospectively. Bypasses to infrapopliteal ar-
teries performed with HUV-composite grafts were reviewed for graft patency, limb salvage, patient survival and possible
biodegeneration of the HUV.
Results. Early graft thrombosis was noted in 21.3%, necessitating revision surgery. Primary, primary assisted and sec-
ondary patency rates were 35%, 40% and 42% respectively, with a limb salvage rate of 87% after 5 years. Graft infection
occurred in 7 limbs. Aneurysmal HUV graft degeneration was not detected by duplex scanning.
Conclusion. HUV-composite bypasses provide acceptable patency and favorable limb salvage rates. Patency was similar to
previous series using PTFE-composite bypasses but was significantly inferior to vein bypass. Possible biodegradation of the
HUV grafts seems to be of minor clinical relevance.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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In 1976 Dardik reported the successful clinical use of
glutaraldehyde stabilized human umbilical veins
(HUV) reinforced with a loose external Polyester
mesh as a new small calibre biologic vascular graft
in femoro-distal bypass.1 Despite promising patency
rates in above and below knee femoro-popliteal
bypass, results in the femoro-distal position were
less favorable.2e7 First generation HUV grafts soon
exhibited a disappointing tendency for early postop-
erative thrombosis and formation of graft aneurysms
due to biodegeneration.8 This resulted in a widespread
reluctance to use any kind of biological vascular pros-
theses in infrainguinal bypass surgery.
*Corresponding author. Dr. A. Neufang, Department of Cardiotho-
racic and Vascular Surgery, Johannes Gutenberg-University School
of Medicine, Langenbeckstrasse 1, 55131 Mainz, Germany.
E-mail address: neufang@mail.uni-mainz.de1078–5884/000583+ 07 $32.00/0  2007 European Society for VascuAfter modification of the tanning process and re-
inforcement of the external Dacron mesh the second
generation of glutaraldehyde stabilized HUV has
been available for infrainguinal arterial reconstruction
for almost two decades. A single centre consecutive
series of femoro-distal bypasses with this modified
HUV-graft, employing the composite technique, has
been assessed for long term graft function, secondary
procedures to maintain or restore patency and limb
salvage.
Patients and Methods
From a total of 2196 infrainguinal bypass operations
performed between January 1996 and July 2006 and
prospectively documented in a computerized data-
base all femoro-distal bypasses to a single outflow
infrapopliteal vessel with HUV as part of a compos-
ite graft were identified. Patient characteristics,lar Surgery. Published by Elsevier Ltd. All rights reserved.
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rospectively from patient charts.
The HUV was only chosen if, after intraoperative
exploration and assessment by the operating surgeon,
sufficient autologous vein was not available. When-
ever possible the anastomosis to a crural or pedal
artery was performed with autologous vein and the
composite technique was preferred when a prosthesis
was used. Composite grafts were used when a seg-
ment of suitable autologous vein was available but
the length of harvested vein was assessed as insuffi-
cient for a complete autogenous reconstruction by
the operating surgeon. To ensure that as much autol-
ogous vein as possible was used in some instances
spliced vein was combined with the HUV.
HUV grafts were rinsed prior to implantation
according to the manufacturers’ rinsing procedure
protocol. Distal anastomoses were constructed under
systemic heparinisation with polypropylene suture
in the conventional end-to-side manner. The compos-
ite anastomosis was performed with vein and HUV
beveled at 45 including the external Dacron mesh
into the suture line. For the proximal anastomosis
the common femoral or the proximal superficial fem-
oral artery were chosen and additional endarterec-
tomy or profundaplasty performed if necessary.
Bypasses were placed preferentially in a subfascial
position using a hollow plastic sheath tunneler. Sub-
cutaneous extra-anatomic placement was only used
in the presence of extensive scarification in the popli-
teal fossa, due to previous bypass procedures.
Graft patency was confirmed by intraoperative
flow measurement (Cardio-Med Medi-Stim, Oslo,
Norway; Transonic Systems, Ithaca, NY, USA) after
completion of the anastomosis. Prior to discharge
another early postoperative duplex scan or angiogra-
phy were performed.
Except for contraindications, oral anticoagulation
with phenprocumon (Marcumar) was started postop-
eratively after continuous intravenous administration
of heparin and additional temporary administration
of combined antiplatelet therapy (Aspirin and
Tyklid or Aspirin and Plavix). This combined anti-
platelet therapy was discontinued when the intended
INR level (2.0 to 2.5) was reached and administration
of phenprocumon (Marcumar) was continued indefi-
nitely. Only in the presence of contraindications for oral
anticoagulation was antiplatelet therapy administered
as the only long term medication.
Follow up examinations were performed after 3, 6,
12, 18 and 24 months with annual surveillance there-
after. Follow up included clinical examination of the
operated limb, ABI measurement, duplex-scan of the
graft and angiography in cases of ipsi- or contralateralEur J Vasc Endovasc Surg Vol 34, November 2007ischaemia. A bypass was assessed as patent according
to the recommended standards for reports dealing
with lower extremity ischaemia.9 Amputation with
a patent graft or infection of a patent graft with subse-
quent replacement was considered as graft failure. All
follow-up data were prospectively entered in a com-
puterized data base (ACCESS 2000 for windows)
and analysed (SPSS for Windows, version 11.0; Chi-
cago, Ill, USA) with Kaplan-Meier and log-rank test
( p-value< 0.05 significant) according to the regula-
tions for clinical studies of the ethics committee of
the state of Rhineland-Palatinate, Germany.
Results
89 femoro-distal bypasses were performed in 46 men
and 39 women (85 patients) with a mean age of
74 8.9 years. Three patients underwent bilateral sur-
gery, one subsequently (staged) and two simulta-
neously. In one patient the same leg was reoperated
with the same technique. Some bypasses (35%) were
placed in a subcutaneous position. Preoperative ABI
of the operated limb was 0.32 0.27. Patient charac-
teristics, risk factors, indications for surgery and pre-
vious ipsilateral vascular operations or interventions
and inflow procedures are listed in Tables 1 and 2.
Operative details are listed in Table 3.
Early results
In hospital mortality was 4.6%, with four patients ex-
periencing fatal cardiac events, in one instance after
simultaneous bilateral operations. 25 systemic compli-
cations were noted in 22 patients leading to a com-
bined mortality and morbidity of 25.3%. Early
Table 1. Patient demographics
No. of patients n¼ 85* %
Mean age 74.8 8.9y (49.6e95.8y)
Female 39 45.9
Male 46 54.1
Risk factors
Hypertension 81 95.3
Hyperlipidemia 54 63.5
Diabetes 55 64.7
Smoking 28 33.0
CAD 60 70.6
CVA 16 18.8
ESRD 5 6.5
CAD: coronary artery disease; CVA: cerebrovascular accident;
ESRD: end stage renal disease.
* Three patients with bilateral operation, one patient with subse-
quent reoperation of the same leg.
585Femorodistal HUV-composite Bypasspostoperative failure was noted in 19 bypasses
(21.3%) after a mean of 5.8 days. Revision was initi-
ated in 15 cases and patency could be restored in 12
bypasses by means of simple graft thrombectomy
(11) and partial replacement of the venous component
in one case. New bypasses were constructed in two
patients. Subsequently four of the revised bypasses
developed infection and were replaced with spliced
superficial femoral vein (2) and other alternative ve-
nous segments or a silver impregnated Dacron graft
(1) or in the fourth case resulted in amputation despite
patency. Graft revision was not successful in two
cases, in three cases revision of the thrombosed graft
was not intended and major amputation within 30
days was necessary in two of these patients. In one
patient bleeding from a varicose segment of the ve-
nous bypass component necessitated subtotal replace-
ment with new HUV. Additional early local
complications are listed in Table 4.
Late results
Median (mean) follow-up was 26 (37) months (1e116
months) and one patient was lost to follow-up after 48
months. 41 patients died during follow up from car-
diovascular events or tumor leading to a 5-year sur-
vival of 50%.
Bypass occlusion during follow-up was noted in
30 legs necessitating secondary intervention by
Table 2. Indications for bypass surgery, previous ipsilateral oper-
ations or interventions and inflow procedures
No. of operations
n¼ 89
%
Rest pain 21 23.6
Necrosis/ulceration 65 73.0
Acute deterioration
of chronic ischaemia
3 3.4
Previous ipsilateral operation 34 38.2
Bypass 29 24.3
Profundaplasty 2 5.1
Thrombectomy 3 2.6
Ipsilateral vein partially
harvested previously
39 43.8
Previous ipsilateral intervention 10 11.2
PTA (stent) 9 10.1
Thrombolysis 1 1.1
Inflow procedure (operation) 13 14.6
Aortofemoral bypass 8 9.0
Iliofemoral bypass 1 1.1
Crossover bypass 4 4.5
Inflow procedure (intervention) 5 5.6
PTA (stent) common
iliac artery
4 (3) 4.5 (3.4)
PTA external
iliac artery
1 1.1thrombectomy, distal graft extension or partial re-
placement and redo bypass in 16 cases. Eight patients
could be managed conservatively with preservation
of a viable limb. Six legs were amputated without fur-
ther attempts at revascularisation and one leg was
amputated after unsuccessful revision. Thrombec-
tomy was never successful in restoring further undis-
turbed patency: either patiency could not be restored
or the bypass reoccluded at a later point. 14 new by-
passes were constructed, in five cases after various at-
tempts to restore or maintain patency of the
composite graft, in two cases with spliced arm veins.
In four of these redo bypasses the venous part of the
failed composite bypass was anastomosed with
a new HUV. (details see also Table 5) Within the first
four postoperative months three further infections of
subcutaneously placed HUVs were noted, each of
them after postoperative haematoma or lymph fistula.
Successful partial (2) or total (1) replacement of the
infected prosthesis with superficial femoral vein was
Table 3. Operative details of 89 HUV-composite bypasses
Operative details Number of operations: 89 %
Proximal anastomosis
Common femoral 70 78.7
Proximal superficial femoral 5 5.6
Profunda femoris 3 3.4
Aortofemoral bypass 6 6.7
Crossover bypass 4 4.5
Infrainguinal bypass 1 1.1
Distal anastomosis
proximal and middle calf
69 77
Tibioperoneal trunc 3 3.4
Posterior tibial 13 14.6
Peroneal 36 40.4
Anterior tibial 17 19.1
Distal anastomosis
at ankle and foot
20 23
Posterior tibial 3 3.4
Peroneal 3 3.4
Anterior tibial 7 7.9
Dorsalis pedis 7 7.9
Proximal part HUV
HUV 6 mm diameter 40 44.9
HUV 5 mm diameter 49 55.1
Distal part
Greater saphenous
vein ipsilateral*
60 67.4
Greater saphenous
vein contralateral**
14 15.7
Lesser saphenous
ispi- or contralateral
4 4.5
Arm vein*** 9 10.1
Superficial femoral vein 2 2.2
Extraanatomic bypass course 31 34.8
Anatomic bypass course 58 65.2
* Spliced with additional saphenous or alternative vein in 6 cases.
** Spliced with additional saphenous or alternative vein in 2 cases.
*** Spliced with additional saphenous or alternative vein in 2 cases.Eur J Vasc Endovasc Surg Vol 34, November 2007
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or other signs of biodegradation were not detected
by means of duplex ultrasonography. Primary, pri-
mary assisted and secondary patency rates were
35%, 40% and 42% respectively after 5 years, with
a limb salvage rate of 87% (see also Fig. 1). Results
were in the direction of improved patency for anatom-
ically placed grafts (Fig. 2) and a better outcome for
grafts to the proximal and middle calf in regards of
patency (Fig. 3) and limb salvage.
Discussion
The use of suitable vein segments combined with syn-
thetic grafts was introduced soon after peripheral
bypass became a more widely used operation.10 As
this technique did not exhibit a significant advantage
for primary popliteal bypass it has not been recom-
mended for routine use.11 For infrapopliteal bypass,
the best long term results are achieved with saphe-
nous vein grafts, which provide satisfactory long
term patency and limb salvage. Many authors empha-
size the role of the in situ technique with favorable
long term results12,13 and excellent results for ankle
and pedal bypasses with autologous vein have been
reported.14 Others recommend the use of alternative
sources of vein before prosthetic material is considered
Table 4. Early postoperative (30 days) complications
No. of operations 87*;
no of patients 85
%
Mortality (MI, cardiac failure) 4 4.6
MI, cardiac
failure; arrhythmia
14 16.1
Stroke 0 0
Respiratory failure 2 2.3
Sepsis 1 1.1
Delirium 5 5.7
Others 3 3.4
Combined mortality
and morbidity**
22 25.3
Graft occlusion 19 21.3
Operative revision performed 15
Patency restored 12
New bypass 3
Major amputation 2 2.2
Graft infection 3 3.4
Hematoma (surgical revision) 2 2.2
Wound infection,
lymph fistula, delayed
wound healing
12 13.5
MI: myocardial infarction.
* Two patients operated simultaneously bilateral.
** 25 systemic vascular and nonvascular complications in 22
patients.Eur J Vasc Endovasc Surg Vol 34, November 2007Table 5. Late postoperative (>30 days) complications
Median (mean) follow-up
26 (37) months (1.0e116 months)
No. of
operations
n¼ 89
%
Death (cardiovascular, tumor) 41 48.2
Graft occlusion 30 33.7
No revision 14 15.7
Amputation 6
Conservative management 8
Operative revision performed 16 18.0
Thrombectomy 5
Successful 0
New bypass after revision* 5 5.6
HUV or Omniflow** 5
New bypass without
revision
9 10.1
Arm vein 2
HUV or Omniflow*** 7
Major amputation
With patent
graft (infection, 2 mo)
1 1.1
Occluded graft
(after revision 2)
8 9.0
Graft infection
(successful replacement)****
4 (3) 4.5
Aneurysmal degeneration 0 0
* Previous thrombectomy or patch angioplasty; PTA or partial
graft replacement to restore or maintain patency.
** Anastomosis to the venous part of composite graft in one case.
*** Anastomosis to the venous part of composite graft in three
cases.
**** Infection rate together with three early infections 7.9%.
Fig. 1. Primary patency, secondary patency and limb salvage
in 89 HUV-composite bypasses to infrapopliteal arteries.
587Femorodistal HUV-composite Bypassand reported superior patency compared to synthetic
grafts.15
In cases of insufficient vein, prosthetic material
must be considered. As the results with synthetic
bypasses and direct anastomoses to small vessels are
generally not regarded as satisfactory, modified
Fig. 2. Secondary patency and graft course of 89 HUV-
composite bypasses to infrapopliteal arteries.
Fig. 3. Secondary patency and bypass length of 89 HUV-
composite bypasses to infrapopliteal arteries.anastomoses with vein cuffs in combination with
PTFE have been used and shown to improve pa-
tency.16,17 Historically there has been no clear advan-
tage for the combination of suitable vein segments
with a PTFE prosthesis compared to a complete pros-
thetic bypass with a poor 5-year patency of 28%.18
However, a modern series has reported a favorable
outcome for PTFE-composite grafts with a long term
patency for single outflow PTFE-composite grafts
with a late patency of 56% and a limb salvage rate
of 53%.19 Karacagil showed similar results for com-
posite or cuffed PTFE bypasses, with a 3 year patency
rate of 25% and a limb salvage rate of 55%.20 Bastou-
nis reported promising results in 96 PTFE saphenous
vein composite grafts for popliteal and infrapopliteal
bypass with a 5-year secondary patency of 75% and
a limb salvage rate of 80%.21 Whereas the results of
these series clearly support the combined use of syn-
thetic and autologous material, Faries demonstrated
a clear advantage for spliced arm veins over PTFE
composite grafts with a 5-year patency and limb sal-
vage of 57% and 76% for arm veins versus 0% for
PTFE composite grafts.15 Therefore every effort
should be made to use autologous reconstruction
before the composite technique is considered.
Two randomized studies comparing the perfor-
mance of HUV and PTFE in femoropopliteal position
have shown significantly better results for HUV22,23
and therefore its use was introduced in crural and
pedal bypass. Encouraging results with this graft in
sequential distal bypass for limb salvage have been re-
ported previously, with a high limb salvage rate.24
This significantly better outcome might be explained
by the different angiographic pattern with preserva-
tion of a patent popliteal or proximal crural segment
in many cases. Our series of single outflow crural
and pedal HUV-composite bypasses had a disappoint-
ing rate of early graft failure, necessitating further
interventions with a high rate of graft infections (7.8%,
four after early revision) in the first 6 months with
the need for further complicated interventions,
although patency and limb salvage could be preserved
in five of seven cases. Also the later use of arm veins
indicates that the possibility of using these at the ini-
tial procedure had been underestimated, since there
were two redo procedures (for graft occlusion) using
arm vein grafts. It is noteable that late occlusion could
not be successfully treated by means of simple throm-
bectomy and that most service interventions to avoid
bypass failure were not successful. However, in many
cases the anastomosed peripheral artery remained
patent after bypass failure and successful reoperation
either with a new biological graft or arm veins was
possible. This might be explained by the presence ofEur J Vasc Endovasc Surg Vol 34, November 2007
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tolerate low arterial flow in the anastomotic region in
cases of proximal bypass thrombosis. In addition
a considerable number of legs remained viable de-
spite no further intervention. This is reflected by the
high limb salvage rate of over 80% after 5 years,
higher than the reported lower rates for PTFE with
vein cuffs or vein patches.25e27 The only recent favor-
able results for crural bypasses with PTFE and a distal
vein patch were published by Neville.28
An advantage of the composite technique might be
that the venous part of the bypass may be preserved
in case of prosthetic occlusion and can be used as
recipient site for a new bypass. In our series this
was possible in four cases. There exist very few recent
data about HUV-composites. Feinberg found a disap-
pointing patency and limb salvage rate in 21 HUV-
composite bypasses, due to a very high rate of early
thrombosis and anastomotic disruption. Therefore,
these authors abandoned the use of HUV in compos-
ite grafts.29 The only available modern series of crural
bypass with HUV using the adjunctive common os-
tium AV fistula reported by Dardik showed a 6 year
patency of 47% with a limb salvage rate of 61%.30
Our reported series of 89 operations compares favor-
able with the published patency rates for PTFE-
composite and enabled a promising limb salvage
rate, but at the price of a high rate of secondary
interventions.
The historically reported tendency for aneurysm
formation seems to be of minor clinical relevance in
this subgroup of patients with critical ischaemia. A re-
cent analysis by Strobel found an incidence of 16% in
their series of 108 HUV bypasses with a low late inter-
vention rate.31
Conclusion
HUV-composite bypasses provide success with
respect to late patency and but carry a significant
risk of early infection and a need for secondary inter-
ventions. Limb salvage seems to be favourable.
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